CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer.
Cancer Genet
; 284-285: 34-42, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38626533
ABSTRACT
Circular RNAs (circRNAs) play an important role in the development of acquired resistance to many anticancer drugs. We developed the Non-Small-Cell Lung Cancer (NSCLC) cell lines with acquired resistance to osimertinib, a third-generation of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), and evaluated the different expression profiles of circRNAs in osimertinib-sensitive and -resistant NSCLC cell lines using RNA sequencing (RNA-Seq). The expression of selected differentially expressed circRNAs was verified using quantitative real-time PCR (qRT-PCR) in paired osimertinib-sensitive and -resistant NSCLC cell lines, and in plasma samples of osimertinib-sensitive and -resistant NSCLC patients. We found that circMYBL1(has_circ_0136924) was downregulated after acquired resistance to osimertinib, inhibiting circMYBL1 expression facilitated the proliferation, migration, and invasion in osimertinib-sensitive NSCLC cells. CircMYBL1 may be a novel molecular biomarker and therapeutic target for osimertinib-resistant NSCLC.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acrylamides
/
Carcinoma, Non-Small-Cell Lung
/
Drug Resistance, Neoplasm
/
RNA, Circular
/
Aniline Compounds
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer Genet
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: